Patent application number | Description | Published |
20080311588 | NEUROGENIN - The invention relates to novel neurogenin proteins, nucleic acids and antibodies. | 12-18-2008 |
20090087434 | NFIA IN GLIAL FATE DETERMINATION, GLIOMA THERAPY AND ASTROCYTOMA TREATMENT - Disclosed herein are compositions comprising NFIA inhibitors, as well as methods of using the same to treat glioma and astrocytomas. | 04-02-2009 |
20100130419 | Artery- and Vein-Specific Proteins and Uses Therefor - Arterial and venous endothelial cells are molecularly distinct from the earliest stages of angiogenesis. This distinction is revealed by expression on arterial cells of a transmembrane ligand, called EphrinB2 whose receptor EphB4 is expressed on venous cells. Targeted disruption of the EphrinB2 gene prevents the remodeling of veins from a capillary plexus into properly branched structures. Moreover, it also disrupts the remodeling of arteries, suggesting that reciprocal interactions between pre-specified arterial and venous endothelial cells are necessary for angiogenesis. This distinction can be used to advantage in methods to alter angiogenesis, methods to assess the effect of drugs on artery cells and vein cells, and methods to identify and isolate artery cells and vein cells, for example. | 05-27-2010 |
20100266615 | D1-1 NUCLEIC ACIDS, POLYPEPTIDES AND RELATED METHODS - The disclosure provides, among other things, novel angiogenesis-related nucleic acids, polypeptides and methods of use. | 10-21-2010 |
20110150769 | IDENTIFICATION AND USE OF COMPOUNDS FOR TREATING PERSISTENT PAIN - The present application provides methods and compositions that can be used to treat persistent pain and to identify compounds that can be used for treating persistent pain. More specifically, agonists of members of the Mrgpr receptor family, particularly agonists of MrgprX1, can identified and screened for use in treating persistent pain, such as pain caused by inflammation or nerve injury. | 06-23-2011 |
20110195901 | ARTERY- AND VEIN-SPECIFIC PROTEINS AND USES THEREFOR - Arterial and venous endothelial cells are molecularly distinct from the earliest stages of angiogenesis. This distinction is revealed by expression on arterial cells of a transmembrane ligand, called EphrinB2 whose receptor EphB4 is expressed on venous cells. Targeted disruption of the EphrinB2 gene prevents the remodeling of veins from a capillary plexus into properly branched structures. Moreover, it also disrupts the remodeling of arteries, suggesting that reciprocal interactions between pre-specified arterial and venous endothelial cells are necessary for angiogenesis. This distinction can be used to advantage in methods to alter angiogenesis, methods to assess the effect of drugs on artery cells and vein cells, and methods to identify and isolate artery cells and vein cells, for example. | 08-11-2011 |
20110287480 | NEUROGENIN - The invention relates to novel neurogenin proteins, nucleic acids and antibodies. | 11-24-2011 |
20120073001 | METHODS AND COMPOSITIONS FOR TREATING OR PREVENTING PRURITIS - The invention features therapeutic compositions comprising agents useful for the treatment or prevention of pruritis, and methods useful for identifying such agents. | 03-22-2012 |
20130091591 | ARTERY- AND VEIN-SPECIFIC PROTEINS AND USES THEREFOR - Arterial and venous endothelial cells are molecularly distinct from the earliest stages of angiogenesis. This distinction is revealed by expression on arterial cells of a transmembrane ligand, called EphrinB2 whose receptor EphB4 is expressed on venous cells. Targeted disruption of the EphrinB2 gene prevents the remodeling of veins from a capillary plexus into properly branched structures. Moreover, it also disrupts the remodeling of arteries, suggesting that reciprocal interactions between pre-specified arterial and venous endothelial cells are necessary for angiogenesis. This distinction can be used to advantage in methods to alter angiogenesis, methods to assess the effect of drugs on artery cells and vein cells, and methods to identify and isolate artery cells and vein cells, for example. | 04-11-2013 |
20130165385 | NEUROGENIN - The invention relates to novel neurogenin proteins, nucleic acids and antibodies. | 06-27-2013 |
20140178305 | IDENTIFICATION AND USE OF ANXIOLYTIC COMPOUNDS - The present disclosure provides methods and compositions that can be used to identify anxiolytic compounds, and to treat anxiety in a subject. Methods and compositions for identifying activating stimuli for sensory neurons, for example MrgprB4 | 06-26-2014 |
20140303231 | METHODS AND COMPOSITIONS FOR TREATING OR PREVENTING PRURITIS - The invention features therapeutic compositions comprising agents useful for the treatment or prevention of pruritis, and methods useful for identifying such agents. | 10-09-2014 |
20140351960 | ARTERY- AND VEIN-SPECIFIC PROTEINS AND USES THEREFOR - Arterial and venous endothelial cells are molecularly distinct from the earliest stages of angiogenesis. This distinction is revealed by expression on arterial cells of a transmembrane ligand, called EphrinB2 whose receptor EphB4 is expressed on venous cells. Targeted disruption of the EphrinB2 gene prevents the remodeling of veins from a capillary plexus into properly branched structures. Moreover, it also disrupts the remodeling of arteries, suggesting that reciprocal interactions between pre-specified arterial and venous endothelial cells are necessary for angiogenesis. This distinction can be used to advantage in methods to alter angiogenesis, methods to assess the effect of drugs on artery cells and vein cells, and methods to identify and isolate artery cells and vein cells, for example. | 11-27-2014 |